Press Releases

Orexo AB (publ.) announces today that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI (GS248), a drug candidate for the treatment of systemic sclerosis, has been granted Orphan Drug Designation in the US by the Food and Drug Administration (FDA). Systemic sclerosis (also known as scleroderma) is a chronic, autoimmune disease that affects, among other things, the body's smallest vessels, the microvasculature, and is associated with great medical

Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that it has been granted new drug product exclusivity by the U.S. Food and Drug Administration (FDA) for GIMOTI (metoclopramide) nasal spray. Evoke now has exclusive marketing rights over a period of three (3) years from the original date of approval under the Hatch-Waxman Act to protect the product from generic drug competition. Enacted by Congress in 198

Tribun Health (Formerly Tribvn Healthcare) is pleased to announce the company's expansion into the pharmaceutical market with the appointment of Mr. Loic Dartois as Vice President Pharma. After graduating from ESIEE Management Paris in Biotechnologies, Loic started his career at Sanofi as a product manager, where he was able to demonstrate his skills in business development and knowledge of the medical field. Loic quickly became Business Development Director with several companies such as

Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has filed a clinical trial application with the Human Research Ethics Committee (HREC) in Australia in order to initiate the Phase I ATRIUM trial of ATG-018 in patients with advanced solid tumors and hematologic malignancies.

Arrowhead Pharmaceuticals Inc. announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China. The company also announced that it has entered into a license agreement with Visirna, pursuant to which Visirna will have exclusive rights to develop and commercialize four of Arrowhead’s investigational RNA interference (RNAi) therapeutics for cardiometabolic diseases in mainland China, Hong Kong, Macau, and T

Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases. The M201 program is designed for patients with mild to moderate ulcerative colitis. M201 is comprised of a rationally designed consortium of commensal bacteria that were selected ba

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-month review period and includes a required reinspection of the company’s

Nexus Pharmaceuticals announced the launch of Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™. “The launch of Erythromycin Lactobionate showcases Nexus’ commitment to providing critical antibiotics where and when they are needed most,” said Vince LoPiccolo, Vice President of Sales and Marketing at Nexus Pharmaceuticals. “Erythromycin is the first of many upcoming antibiotics that

Labcorp, a leading global life sciences company, is collaborating with Xcell Biosciences, Inc. (Xcellbio), a leading developer of cell and gene therapy technologies, to advance critical work that helps clients effectively bring innovative cell and gene therapies to market. Through their collaboration, Labcorp and Xcellbio will work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). This strengthens Labcorp’s commitment to gr

X-Chem, the leader of DNA-encoded library (DEL) technology and artificial intelligence (AI) for small molecule drug discovery, today announced the availability of XD3 — X-Chem’s Dynamic Drug Discovery ecosystem for biopharma partners and clients. XD3 combines the vast trove of data generated by DEL screening, the analytical and predictive power of X-Chem’s artificial intelligence platform, ArtemisAI, and its deep medicinal chemistry expertise into an end-to-end package desig